Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients by Colucci, S. et al.
ALTERED OSTEOGENIC PROPERTIES OF BONE MARROW STROMAL CELLS
FROM MULTIPLE MYELOMA PATIENTS
S. Colucci1, G. Brunetti1, A. Oranger1, G. Mori1, R. Rizzi2, S. Capalbo2, V. Liso2, M. Grano1
1 Department of Human Anatomy and Histology, University of Bari, Bari, Italy
2 Hematology, University of Bari, Bari, Italy
Multiple myeloma (MM) is a B cell neoplasm characterized by clonal expansion of malignant plasma cells
in the bone marrow (BM) with frequent occurrence of lytic bone disease. It results from an unbalanced
bone turnover with enhanced resorption related to increased OC recruitment and activity and low bone
formation. In particular, the reciprocal relationship between MM cells and OCs is known to be critical for
the induction of osteoclastogenesis and the activation of bone resorption as well as the relationship be-
tween MM cells and OBs could be crucial to affect bone matrix formation, thus preventing lesion repair.
Thus, we investigated the osteogenic properties of bone marrow stromal cells (BMSCs) collected from
patients affected by MM. We demostrated that, culturing BMSCs for 14 days in differentiating conditions,
the induction of ALP expression at mRNA level and activity were completely absent in BMSCs from pa-
tients with multiple myeloma bone disease. Differently, ALP was weakly expressed in BMSCs from pa-
tients with multiple myeloma without osteolysis, and it was strongly evident in the controls. To further in-
vestigate the ability of BMSCs from multiple myeloma patients to differentiate toward the osteoblastic
phenotype, the expression of collagen type I (COLL-I) and the formation of mineralized nodules were
evaluated respect to BMSCs from the controls. Low basal mRNA levels of COLL-I were detected in BM-
SCs from multiple myeloma bone disease patients before the incubation with osteogenic medium. The
mRNA levels were further reduced in these cells after 7 and 14 days of culture in differentiating condi-
tions. In addition, no COLL-I expression was detected at protein levels in the BMSC lysates from the
same patients. The mineralized nodule formation did not occur in BMSCs from multiple myeloma bone
disease patients despite the incubation with osteogenic medium for 4 weeks. Differently, a substantial
mineralization was detected in BMSCs from multiple myeloma patients without osteolytic lesions, and, as
expected, significantly higher mineralization areas were detected in the controls as demonstrated by
quantitative analysis of Von Kossa staining. In conclusion, our results demonstrated that the BMSCs from
MM bone disease patients show a reduced capability to differentiate toward an osteoblastic phenotype.
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